116 related articles for article (PubMed ID: 1555749)
1. Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice.
Funakoshi A; Kono A
Gastroenterol Jpn; 1992 Feb; 27(1):78-82. PubMed ID: 1555749
[TBL] [Abstract][Full Text] [Related]
2. [Effects of UFT and loxiglumide (CR1505) on liver metastasis of human pancreatic cancer cell line, KP-1 N in nude mice].
Shimazoe T; Funakoshi A; Kono A
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1321-5. PubMed ID: 1503487
[TBL] [Abstract][Full Text] [Related]
3. Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice.
Nio Y; Tsubono M; Morimoto H; Kawabata K; Masai Y; Hayashi H; Manabe T; Imamura M; Fukumoto M
Cancer; 1993 Dec; 72(12):3599-606. PubMed ID: 8252474
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of a cholecystokinin antagonist, loxiglumide (CR-1505), on the growth of freshly separated and xenografted human pancreatic cancer.
Morimoto H; Nio Y; Tsubono M; Tseng CC; Kawabata K; Masai Y; Hayashi H; Baba N; Manabe T; Hosokawa Y
J Surg Oncol; 1993 May; 53(1):47-53. PubMed ID: 8386784
[TBL] [Abstract][Full Text] [Related]
5. Effect of proglumide, a cholecystokinin receptor antagonist, on caerulein-stimulated pancreatic enzyme secretion and pancreatic polypeptide release in the dog.
Fried M; Beglinger C; Koehler E; Whitehouse I; Varga L; Gyr K
Regul Pept; 1984 Mar; 8(2):117-22. PubMed ID: 6729149
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice.
Ikeda Y; Ezaki M; Hayashi I; Yasuda D; Nakayama K; Kono A
Jpn J Cancer Res; 1990 Oct; 81(10):987-93. PubMed ID: 2172194
[TBL] [Abstract][Full Text] [Related]
7. Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat.
Sperti C; Militello C; Rovati L; Behboo R; Khajeturian E; Perasole A; Alaggio R; Pedrazzoli S
J Surg Oncol; 1994 Sep; 57(1):11-6. PubMed ID: 8065144
[TBL] [Abstract][Full Text] [Related]
8. Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas.
Douglas BR; Woutersen RA; Jansen JB; de Jong AJ; Rovati LC; Lamers CB
Cancer Res; 1989 May; 49(9):2438-41. PubMed ID: 2706631
[TBL] [Abstract][Full Text] [Related]
9. Effect of the cholecystokinin-receptor antagonist lorglumide on pancreatic enzyme secretion stimulated by bombesin, food, and caerulein, giving similar plasma cholecystokinin concentrations in the dog.
de Jong AJ; Singer MV; Jansen JB; Niebel W; Rovati LC; Lamers CB
Gut; 1991 Feb; 32(2):215-9. PubMed ID: 1864545
[TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990.
Smith JP; Solomon TE; Bagheri S; Kramer S
Dig Dis Sci; 1990 Nov; 35(11):1377-84. PubMed ID: 2226098
[TBL] [Abstract][Full Text] [Related]
11. Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat.
Scarpignato C; Varga G; Dobronyi I; Papp M
Br J Pharmacol; 1989 Mar; 96(3):661-9. PubMed ID: 2470456
[TBL] [Abstract][Full Text] [Related]
12. Biological effects of a proglumide derivative as cholecystokinin antagonist in conscious dogs.
Hildebrand P; Beglinger C; Köhler E; Setnikar I; Gyr K
Regul Pept; 1987 Aug; 18(3-4):213-20. PubMed ID: 3446223
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin in the hormonal stimulation of amino acid uptake and pancreatic enzyme secretion.
Konturek JW; Gabryelewicz A; Stoll R; Domschke W
Ann N Y Acad Sci; 1994 Mar; 713():454-6. PubMed ID: 7514376
[No Abstract] [Full Text] [Related]
14. Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas.
Douglas BR; Woutersen RA; Jansen JB; de Jong AJ; Rovati LC; Lamers CB
Gastroenterology; 1989 Feb; 96(2 Pt 1):462-9. PubMed ID: 2910761
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin receptor antagonism by peptidergic and non-peptidergic agents in rat pancreas.
Dembinski A; Jaworek J; Konturek PK; Konturek SJ; Warzecha Z
J Physiol; 1989 Apr; 411():419-35. PubMed ID: 2614728
[TBL] [Abstract][Full Text] [Related]
16. Proglumide analogues CR 1409 and CR 1392 inhibit cholecystokinin-stimulated insulin release more potently than exocrine secretion from the isolated perfused rat pancreas.
Okabayashi Y; Otsuki M; Nakamura T; Fujii M; Tani S; Fujisawa T; Koide M; Hasegawa H; Baba S
Pancreas; 1990 May; 5(3):291-7. PubMed ID: 2188254
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo.
Niederau M; Niederau C; Strohmeyer G; Grendell JH
Am J Physiol; 1989 Jan; 256(1 Pt 1):G150-7. PubMed ID: 2463767
[TBL] [Abstract][Full Text] [Related]
18. Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide.
Meijers M; Appel MJ; van Garderen-Hoetmer A; Lamers CB; Rovati LC; Jansen JB; Woutersen RA
Carcinogenesis; 1992 Sep; 13(9):1525-8. PubMed ID: 1394835
[TBL] [Abstract][Full Text] [Related]
19. Effects of a new proglumide analogue CR 1392 on pancreatic exocrine secretion in the rat.
Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
Digestion; 1989; 42(2):61-9. PubMed ID: 2475379
[TBL] [Abstract][Full Text] [Related]
20. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
